New approaches to the treatment of dense deposit disease

Richard J.H. Smith, Jessy Alexander, Paul N. Barlow, Marina Botto, Thomas L. Cassavant, H. Terence Cook, Santiago Rodriguez De Córdoba, Gregory S. Hageman, T. Sakari Jokiranta, William J. Kimberling, John D. Lambris, Lynne D. Lanning, Vicki Levidiotis, Christoph Licht, Hans U. Lutz, Seppo Meri, Matthew C. Pickering, Richard J. Quigg, Angelique L. Rops, David J. SalantSanjeev Sethi, Joshua M. Thurman, Hope F. Tully, Sean P. Tully, Johan Van Der Vlag, Patrick D. Walker, Reinhard Würzner, Peter F. Zipfel

Research output: Contribution to journalReview article

187 Citations (Scopus)

Abstract

The development of clinical treatment protocols usually relies on evidence-based guidelines that focus on randomized, controlled trials. For rare renal diseases, such stringent requirements can represent a significant challenge. Dense deposit disease (DDD; also known as membranoproliferative glomerulonephritis type II) is a prototypical rare disease. It affects only two to three people per million and leads to renal failure within 10 yr in 50% of affected children. On the basis of pathophysiology, this article presents a diagnostic and treatment algorithm for patients with DDD. Diagnostic tests should assess the alternative pathway of complement for abnormalities. Treatment options include aggressive BP control and reduction of proteinuria, and on the basis of pathophysiology, animal data, and human studies, plasma infusion or exchange, rituximab, sulodexide, and eculizumab are additional options. Criteria for treatment success should be prevention of progression as determined by maintenance or improvement in renal function. A secondary criterion should be normalization of activity levels of the alternative complement pathway as measured by C3/C3d ratios and C3NeF levels. Outcomes should be reported to a central repository that is now accessible to all clinicians. As the understanding of DDD increases, novel therapies should be integrated into existing protocols for DDD and evaluated using an open-label Bayesian study design.

Original languageEnglish (US)
Pages (from-to)2447-2456
Number of pages10
JournalJournal of the American Society of Nephrology
Volume18
Issue number9
DOIs
StatePublished - Sep 1 2007

Fingerprint

Membranoproliferative Glomerulonephritis
Dichlorodiphenyldichloroethane
Alternative Complement Pathway
Clinical Protocols
Rare Diseases
Kidney
Therapeutics
Proteinuria
Routine Diagnostic Tests
Renal Insufficiency
Randomized Controlled Trials
Maintenance
Guidelines

ASJC Scopus subject areas

  • Nephrology

Cite this

Smith, R. J. H., Alexander, J., Barlow, P. N., Botto, M., Cassavant, T. L., Cook, H. T., ... Zipfel, P. F. (2007). New approaches to the treatment of dense deposit disease. Journal of the American Society of Nephrology, 18(9), 2447-2456. https://doi.org/10.1681/ASN.2007030356

New approaches to the treatment of dense deposit disease. / Smith, Richard J.H.; Alexander, Jessy; Barlow, Paul N.; Botto, Marina; Cassavant, Thomas L.; Cook, H. Terence; De Córdoba, Santiago Rodriguez; Hageman, Gregory S.; Jokiranta, T. Sakari; Kimberling, William J.; Lambris, John D.; Lanning, Lynne D.; Levidiotis, Vicki; Licht, Christoph; Lutz, Hans U.; Meri, Seppo; Pickering, Matthew C.; Quigg, Richard J.; Rops, Angelique L.; Salant, David J.; Sethi, Sanjeev; Thurman, Joshua M.; Tully, Hope F.; Tully, Sean P.; Van Der Vlag, Johan; Walker, Patrick D.; Würzner, Reinhard; Zipfel, Peter F.

In: Journal of the American Society of Nephrology, Vol. 18, No. 9, 01.09.2007, p. 2447-2456.

Research output: Contribution to journalReview article

Smith, RJH, Alexander, J, Barlow, PN, Botto, M, Cassavant, TL, Cook, HT, De Córdoba, SR, Hageman, GS, Jokiranta, TS, Kimberling, WJ, Lambris, JD, Lanning, LD, Levidiotis, V, Licht, C, Lutz, HU, Meri, S, Pickering, MC, Quigg, RJ, Rops, AL, Salant, DJ, Sethi, S, Thurman, JM, Tully, HF, Tully, SP, Van Der Vlag, J, Walker, PD, Würzner, R & Zipfel, PF 2007, 'New approaches to the treatment of dense deposit disease', Journal of the American Society of Nephrology, vol. 18, no. 9, pp. 2447-2456. https://doi.org/10.1681/ASN.2007030356
Smith RJH, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT et al. New approaches to the treatment of dense deposit disease. Journal of the American Society of Nephrology. 2007 Sep 1;18(9):2447-2456. https://doi.org/10.1681/ASN.2007030356
Smith, Richard J.H. ; Alexander, Jessy ; Barlow, Paul N. ; Botto, Marina ; Cassavant, Thomas L. ; Cook, H. Terence ; De Córdoba, Santiago Rodriguez ; Hageman, Gregory S. ; Jokiranta, T. Sakari ; Kimberling, William J. ; Lambris, John D. ; Lanning, Lynne D. ; Levidiotis, Vicki ; Licht, Christoph ; Lutz, Hans U. ; Meri, Seppo ; Pickering, Matthew C. ; Quigg, Richard J. ; Rops, Angelique L. ; Salant, David J. ; Sethi, Sanjeev ; Thurman, Joshua M. ; Tully, Hope F. ; Tully, Sean P. ; Van Der Vlag, Johan ; Walker, Patrick D. ; Würzner, Reinhard ; Zipfel, Peter F. / New approaches to the treatment of dense deposit disease. In: Journal of the American Society of Nephrology. 2007 ; Vol. 18, No. 9. pp. 2447-2456.
@article{4cf6fe47abff4f9e9df2d4b1801eb647,
title = "New approaches to the treatment of dense deposit disease",
abstract = "The development of clinical treatment protocols usually relies on evidence-based guidelines that focus on randomized, controlled trials. For rare renal diseases, such stringent requirements can represent a significant challenge. Dense deposit disease (DDD; also known as membranoproliferative glomerulonephritis type II) is a prototypical rare disease. It affects only two to three people per million and leads to renal failure within 10 yr in 50{\%} of affected children. On the basis of pathophysiology, this article presents a diagnostic and treatment algorithm for patients with DDD. Diagnostic tests should assess the alternative pathway of complement for abnormalities. Treatment options include aggressive BP control and reduction of proteinuria, and on the basis of pathophysiology, animal data, and human studies, plasma infusion or exchange, rituximab, sulodexide, and eculizumab are additional options. Criteria for treatment success should be prevention of progression as determined by maintenance or improvement in renal function. A secondary criterion should be normalization of activity levels of the alternative complement pathway as measured by C3/C3d ratios and C3NeF levels. Outcomes should be reported to a central repository that is now accessible to all clinicians. As the understanding of DDD increases, novel therapies should be integrated into existing protocols for DDD and evaluated using an open-label Bayesian study design.",
author = "Smith, {Richard J.H.} and Jessy Alexander and Barlow, {Paul N.} and Marina Botto and Cassavant, {Thomas L.} and Cook, {H. Terence} and {De C{\'o}rdoba}, {Santiago Rodriguez} and Hageman, {Gregory S.} and Jokiranta, {T. Sakari} and Kimberling, {William J.} and Lambris, {John D.} and Lanning, {Lynne D.} and Vicki Levidiotis and Christoph Licht and Lutz, {Hans U.} and Seppo Meri and Pickering, {Matthew C.} and Quigg, {Richard J.} and Rops, {Angelique L.} and Salant, {David J.} and Sanjeev Sethi and Thurman, {Joshua M.} and Tully, {Hope F.} and Tully, {Sean P.} and {Van Der Vlag}, Johan and Walker, {Patrick D.} and Reinhard W{\"u}rzner and Zipfel, {Peter F.}",
year = "2007",
month = "9",
day = "1",
doi = "10.1681/ASN.2007030356",
language = "English (US)",
volume = "18",
pages = "2447--2456",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "9",

}

TY - JOUR

T1 - New approaches to the treatment of dense deposit disease

AU - Smith, Richard J.H.

AU - Alexander, Jessy

AU - Barlow, Paul N.

AU - Botto, Marina

AU - Cassavant, Thomas L.

AU - Cook, H. Terence

AU - De Córdoba, Santiago Rodriguez

AU - Hageman, Gregory S.

AU - Jokiranta, T. Sakari

AU - Kimberling, William J.

AU - Lambris, John D.

AU - Lanning, Lynne D.

AU - Levidiotis, Vicki

AU - Licht, Christoph

AU - Lutz, Hans U.

AU - Meri, Seppo

AU - Pickering, Matthew C.

AU - Quigg, Richard J.

AU - Rops, Angelique L.

AU - Salant, David J.

AU - Sethi, Sanjeev

AU - Thurman, Joshua M.

AU - Tully, Hope F.

AU - Tully, Sean P.

AU - Van Der Vlag, Johan

AU - Walker, Patrick D.

AU - Würzner, Reinhard

AU - Zipfel, Peter F.

PY - 2007/9/1

Y1 - 2007/9/1

N2 - The development of clinical treatment protocols usually relies on evidence-based guidelines that focus on randomized, controlled trials. For rare renal diseases, such stringent requirements can represent a significant challenge. Dense deposit disease (DDD; also known as membranoproliferative glomerulonephritis type II) is a prototypical rare disease. It affects only two to three people per million and leads to renal failure within 10 yr in 50% of affected children. On the basis of pathophysiology, this article presents a diagnostic and treatment algorithm for patients with DDD. Diagnostic tests should assess the alternative pathway of complement for abnormalities. Treatment options include aggressive BP control and reduction of proteinuria, and on the basis of pathophysiology, animal data, and human studies, plasma infusion or exchange, rituximab, sulodexide, and eculizumab are additional options. Criteria for treatment success should be prevention of progression as determined by maintenance or improvement in renal function. A secondary criterion should be normalization of activity levels of the alternative complement pathway as measured by C3/C3d ratios and C3NeF levels. Outcomes should be reported to a central repository that is now accessible to all clinicians. As the understanding of DDD increases, novel therapies should be integrated into existing protocols for DDD and evaluated using an open-label Bayesian study design.

AB - The development of clinical treatment protocols usually relies on evidence-based guidelines that focus on randomized, controlled trials. For rare renal diseases, such stringent requirements can represent a significant challenge. Dense deposit disease (DDD; also known as membranoproliferative glomerulonephritis type II) is a prototypical rare disease. It affects only two to three people per million and leads to renal failure within 10 yr in 50% of affected children. On the basis of pathophysiology, this article presents a diagnostic and treatment algorithm for patients with DDD. Diagnostic tests should assess the alternative pathway of complement for abnormalities. Treatment options include aggressive BP control and reduction of proteinuria, and on the basis of pathophysiology, animal data, and human studies, plasma infusion or exchange, rituximab, sulodexide, and eculizumab are additional options. Criteria for treatment success should be prevention of progression as determined by maintenance or improvement in renal function. A secondary criterion should be normalization of activity levels of the alternative complement pathway as measured by C3/C3d ratios and C3NeF levels. Outcomes should be reported to a central repository that is now accessible to all clinicians. As the understanding of DDD increases, novel therapies should be integrated into existing protocols for DDD and evaluated using an open-label Bayesian study design.

UR - http://www.scopus.com/inward/record.url?scp=34548491156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548491156&partnerID=8YFLogxK

U2 - 10.1681/ASN.2007030356

DO - 10.1681/ASN.2007030356

M3 - Review article

C2 - 17675665

AN - SCOPUS:34548491156

VL - 18

SP - 2447

EP - 2456

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 9

ER -